US OptionsDetailed Quotes
REGN250103C780000
- 3.70
- 0.000.00%
15min DelayClose Jan 3 16:00 ET
0.00High0.00Low
3.70Open3.70Pre Close0 Volume10 Open Interest780.00Strike Price0.00Turnover4588.07%IV9.13%PremiumJan 3, 2025Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry3.70Extrinsic Value100Contract SizeAmericanOptions Type0.1403Delta0.0042Gamma194.09Leverage Ratio-6153.1440Theta0.0000Rho27.24Eff Leverage0.0026Vega
Regeneron Pharmaceuticals Stock Discussion
This information comes from a friend of CNBC Jim Cramer who is also statin intolerant an...
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
$Hershey (HSY.US)$ $Celsius Holdings (CELH.US)$ $Regeneron Pharmaceuticals (REGN.US)$ $Yelp Inc (YELP.US)$ $Innovative Industrial Properties Inc (IIPR.US)$
Crypto: $Coinbase (COIN.US)$ $GEMINI GROUP GLOBAL CORP (GMNI.US)$ $Riot Platforms (RIOT.US)$
Financials: $JPMorgan (JPM.US)$ $Morgan Stanley (MS.US)$ $Wells Fargo & Co (WFC.US)$
Traditional Energy: $Exxon Mobil (XOM.US)$ $Chevron (CVX.US)$ $ConocoPhillips (COP.US)$
Biotechnology: $Amgen (AMGN.US)$ $Gilead Sciences (GILD.US)$ $ROCHE HOLDING AG (RHHBY.US)$ $Biogen (BIIB.US)$ $Regeneron Pharmaceuticals (REGN.US)$
...
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...
Day 1 passed quickly, when I first looked at the US market, it was in the reds. I was at a lost to choose what stocks or ETFs to buy.
I first placed an order in $SPDR S&P 500 ETF (SPY.US)$ to act as a buffer, and managed to get it at the price I wanted.
I then found $Regeneron Pharmaceuticals (REGN.US)$ was dropping quite a bit s...
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
No comment yet